Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases.Hepatology. 2018; 68: 723-750
- Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.Int J Biol Sci. 2020; 16: 1551-1562
- Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA.Mol Cancer. 2019; 18: 114
- Liquid biopsies in hepatocellular carcinoma: are we winning?.J Clin Med. 2020; 9: 1541
- Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver.Am J Surg Pathol. 1998; 22: 656-662
- Hepatic precancerous lesions and small hepatocellular carcinoma.Gastroenterol Clin North Am. 2007; 36 (vii): 867-887
- Update on precursor and early lesions of hepatocellular carcinomas.Arch Pathol Lab Med. 2011; 135: 704-715
- Latest developments in precancerous lesions of hepatocellular carcinoma.World J Gastroenterol. 2016; 22: 3305-3314
- Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia.Hepatology. 2009; 49: 658-664
- Hepatocellular carcinoma.5th edition. IARC, Lyon (France)2019
- Diagnostic approach to hepatic mass lesions and role of immunohistochemistry.Surg Pathol Clin. 2013; 6: 333-365
- Liver precancerous lesions and hepatocellular carcinoma: the histology report.Dig Liver Dis. 2011; 43: S361-S372
- Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules.Cancer. 2007; 109: 915-923
- Immunohistochemical approach for the diagnosis of a liver mass on small biopsy specimens.Hum Pathol. 2017; 63: 1-13
- Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis.Hepatology. 2007; 45: 725-734
- The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma.J Hepatol. 2009; 50: 746-754
- Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma.Gut. 2012; 61: 1481-1487
- Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma.Hepatology. 2003; 37: 198-207
- Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma.Hepatology. 2011; 53: 1549-1557
- Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms.Am J Surg Pathol. 2010; 34: 1147-1154
- Arginase-1 is frequently positive in hepatoid adenocarcinomas.Hum Pathol. 2016; 55: 11-16
- Arginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and glypican-3 in fine-needle aspiration biopsies.Cancer Cytopathol. 2012; 120: 230-237
- A subset of well-differentiated hepatocellular carcinomas are Arginase-1 negative.Hum Pathol. 2017; 69: 90-95
- Well differentiated arginase-1 negative hepatocellular carcinoma.Transl Gastroenterol Hepatol. 2019; 4: 66
- Comparison of 5 immunohistochemical markers of hepatocellular differentiation for the diagnosis of hepatocellular carcinoma.Arch Pathol Lab Med. 2015; 139: 1028-1034
- Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma.Mod Pathol. 2013; 26: 782-791
- Hep Par 1 antibody stain for of hepatocellular carcinoma: the differential diagnosis 676 tumors tested using tissue microarrays and conventional tissue sections.Mod Pathol. 2003; 16: 137-144
- Hepatocyte differentiation markers in adenocarcinoma of the prostate: hepatocyte paraffin 1 but not arginase-1 is specifically expressed in a subset of prostatic adenocarcinoma.Hum Pathol. 2016; 55: 101-107
- A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver.Mod Pathol. 2002; 15: 1279-1287
- Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms.Arch Pathol Lab Med. 2007; 131: 1648-1654
- Hepatocyte antigen as a marker of hepatocellular carcinoma - an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein.Am J Surg Pathol. 2002; 26: 978-988
- The ability to diagnose intrahepatic cholangiocarcinoma definitively using novel branched DNA-enhanced albumin RNA in situ hybridization technology.Ann Surg Oncol. 2016; 23: 290-296
- Branched chain in situ hybridization for albumin as a marker of hepatocellular differentiation: evaluation of manual and automated in situ hybridization platforms.Am J Surg Pathol. 2015; 39: 25-34
- Detection of albumin expression by RNA in situ hybridization is a sensitive and specific method for identification of hepatocellular carcinomas and intrahepatic cholangiocarcinomas.Am J Clin Pathol. 2018; 150: 58-64
- Albumin in situ hybridization can Be positive in adenocarcinomas and other tumors from diverse sites.Am J Clin Pathol. 2019; 152: 190-199
- Low levels of microsatellite instability at simple repeated sequences commonly occur in human hepatocellular carcinoma.Cancer Genomics Proteomics. 2017; 14: 329-339
- Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies.Clin Cancer Res. 2019; 25: 2116-2126
- Molecular therapies and precision medicine for hepatocellular carcinoma.Nat Rev Clin Oncol. 2018; 15: 599-616
- Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features.Hepatology. 2016; 64: 2038-2046
- Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab.Oncotarget. 2018; 9: 10436-10444
- Immunotherapeutic targeting of GPC3 in pediatric solid embryonal tumors.Front Oncol. 2019; 9: 108
- Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence.Cancer Sci. 2003; 94: 851-857
- CK19 and glypican 3 expression profiling in the prognostic indication for patients with HCC after surgical resection.PLoS One. 2016; 11: e0151501
- Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation.J Hepatol. 2015; 63: 1368-1377
- Morphologic subtypes of hepatocellular carcinoma.Gastroenterol Clin North Am. 2017; 46: 365-391
- Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation.Mod Pathol. 2010; 23: 1180-1190
- Fibrolamellar carcinomas are positive for CD68.Mod Pathol. 2011; 24: 390-395
- Fibrolamellar hepatocellular carcinoma: an immunohistochemical comparison with conventional hepatocellular carcinoma.Int J Surg Pathol. 2010; 18: 313-318
- Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.Science. 2014; 343: 1010-1014
- DNAJB1-PRKACA is specific for fibrolamellar carcinoma.Mod Pathol. 2015; 28: 822-829
- DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma.Mod Pathol. 2020; 33: 648-656
- Recurrent rearrangements in PRKACA and PRKACB in intraductal oncocytic papillary neoplasms of the pancreas and bile duct.Gastroenterology. 2020; 158: 573-582.e2
- Phase II multicenter, open-label study of oral ENMD-2076 for the treatment of patients with advanced fibrolamellar carcinoma.Oncologist. 2020; ([Epub ahead of print])
- Clinicopathological study of scirrhous hepatocellular carcinoma.J Gastroenterol Hepatol. 2006; 21: 1470-1477
- 'Scirrhous' type hepatocellular carcinomas: a special reference to expression of cytokeratin 7 and hepatocyte paraffin 1.Histopathology. 2005; 47: 382-390
- Clinicopathologic characteristics and long-term prognosis of scirrhous hepatocellular carcinoma.Dig Dis Sci. 2012; 57: 1698-1707
- Natural history and treatment trends in hepatocellular carcinoma subtypes: insights from a national cancer registry.J Surg Oncol. 2015; 112: 872-876
- Scirrhous hepatocellular carcinoma: comparison with usual hepatocellular carcinoma based on CT-pathologic features and long-term results after curative resection.Eur J Radiol. 2009; 69: 123-130
- Tumor stroma with senescence-associated secretory phenotype in steatohepatitic hepatocellular carcinoma.PLoS One. 2017; 12: e0171922
- The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis.Hum Pathol. 2012; 43: 737-746
- Hepatocellular carcinoma with steatohepatitic features: a clinicopathological study of Japanese patients.Histopathology. 2014; 64: 951-962
- Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.J Hepatol. 2017; 67: 727-738
- beta-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features: immunohistochemical and mutational study.Virchows Arch. 2015; 467: 535-542
- Steatohepatitis-like changes in focal nodular hyperplasia, A finding to distinguish from steatohepatitic variant of hepatocellular carcinoma.Am J Surg Pathol. 2017; 41: 277-281
- The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis.Hum Pathol. 2012; 43 ([author reply: 769–0]): 769
- Macrotrabecular hepatocellular carcinoma: an aggressive subtype of hepatocellular carcinoma.Am J Surg Pathol. 2019; 43: 943-948
- Macrotrabecular-massive hepatocellular carcinoma: a distinctive histological subtype with clinical relevance.Hepatology. 2018; 68: 103-112
- Advances in molecular classification and precision oncology in hepatocellular carcinoma.J Hepatol. 2020; 72: 215-229
- ESM1 as a marker of macrotrabecular-massive hepatocellular carcinoma.Clin Cancer Res. 2019; 25: 5859-5865
- Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration.Hepatology. 1998; 27: 407-414
- Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome.Am J Surg Pathol. 2015; 39: 304-312
- Lymphoepithelioma-like carcinoma in liver.Am J Pathol. 2017; 187: 1438-1444
- Genomic landscape of lymphoepithelioma-like hepatocellular carcinoma.J Pathol. 2019; 249: 166-172
- Granulocyte-colony stimulating factor (G-CSF)-producing esophageal squamous cell carcinoma: a case report.Int Surg. 2014; 99: 280-285
- Neutrophilia associated with anaplastic carcinoma of the thyroid: production of macrophage colony-stimulating factor (M-CSF) and interleukin-6.Thyroid. 2000; 10: 1113-1118
- Granulocyte colony-stimulating factor producing anaplastic carcinoma of the pancreas: case report and review of the literature.Anticancer Res. 2017; 37: 223-228
- Hepatocellular carcinoma producing a granulocyte colony-stimulating factor: report of a resected case with a literature review.Liver Int. 2007; 27: 716-721
- Granulocyte colony-stimulating-factor-producing hepatocellular carcinoma with extensive sarcomatous changes: report of a case.Surg Today. 2013; 43: 439-445
- Granulocyte colony-stimulating factor-producing combined hepatocellular/cholangiocellular carcinoma with sarcomatous change.J Gastroenterol. 2005; 40: 1158-1159
- Clinicopathological and prognostic features of primary clear cell carcinoma of the liver.Hepatol Res. 2008; 38: 291-299
- Therapy and prognostic features of primary clear cell carcinoma of the liver.World J Gastroenterol. 2010; 16: 764-769
- Clinicopathologic study on clear cell hepatocellular carcinoma.Pathol Int. 1996; 46: 503-509
- Clear cell carcinoma of the liver: a comparative immunohistochemical study with renal clear cell carcinoma.Mod Pathol. 2000; 13: 874-881
- Gross anatomic features of hepatocellular carcinoma from three disparate geographic areas. Proposal of new classification.Cancer. 1984; 54: 2165-2173
- Diffuse cirrhosis-like hepatocellular carcinoma: a clinically and radiographically undetected variant mimicking cirrhosis.Am J Surg Pathol. 2010; 34: 935-941
- Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis.J Pathol. 2003; 199: 345-353
- Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas.J Hepatol. 2003; 39: 215-221
- Combination of neoadjuvant transcatheter arterial chemoembolization and orthotopic liver transplantation for the treatment of cirrhotomimetic hepatocellular carcinoma.J Vasc Interv Radiol. 2018; 29: 237-243
- Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features.Mod Pathol. 2013; 26: 1586-1593
- Fibronodular hepatocellular carcinoma-a new variant of liver cancer: clinical, pathological and radiological correlation.J Clin Pathol. 2020; https://doi.org/10.1136/jclinpath-2020-206574
- Combined hepatocellular-cholangiocarcinoma and undifferentiated primary liver carcinoma.5th edition. IARC, Lyon (France)2019
- cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.Hepatology. 2018; 68: 113-126
- Updates in the diagnosis of combined hepatocellular-cholangiocarcinoma.Hum Pathol. 2020; 96: 48-55
- Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors.Cancer. 2002; 94: 2040-2046
- Combined hepatocellular cholangiocarcinoma: prognostic factors investigated by computed tomography/magnetic resonance imaging.Int J Clin Pract. 2008; 62: 1199-1205
- A review on the update of combined hepatocellular cholangiocarcinoma.Semin Liver Dis. 2020; 40: 124-130
- Comprehensive and integrative genomic characterization of hepatocellular carcinoma.Cell. 2017; 169: 1327-1341.e3
- Clinicopathological indices to predict hepatocellular carcinoma molecular classification.Liver Int. 2016; 36: 108-118
- Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma.Hepatology. 2020; 71: 164-182
- A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection.Gastroenterology. 2013; 145: 176-187
Article info
Publication history
Published online: September 03, 2020
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
